Intussusception among infants given an oral rotavirus vaccine.

被引:689
作者
Murphy, TV
Gargiullo, PM
Massoudi, MS
Nelson, DB
Jumaan, AO
Okoro, CA
Zanardi, LR
Setia, S
Fair, E
LeBaron, CW
Schwartz, B
Wharton, M
Livingood, JR
机构
[1] Ctr Dis Control & Prevent, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA 30333 USA
[2] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Immunizat Program, Atlanta, GA 30333 USA
[3] Ctr Dis Control & Prevent, Data Management Div, Natl Immunizat Program, Atlanta, GA 30333 USA
关键词
D O I
10.1056/NEJM200102223440804
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Intussusception is a form of intestinal obstruction in which a segment of the bowel prolapses into a more distal segment. Our investigation began on May 27, 1999, after nine cases of infants who had intussusception after receiving the tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) were reported to the Vaccine Adverse Event Reporting System. Methods: In 19 states, we assessed the potential association between RRV-TV and intussusception among infants at least 1 but less than 12 months old. Infants hospitalized between November 1, 1998, and June 30, 1999, were identified by systematic reviews of medical and radiologic records. Each infant with intussusception was matched according to age with four healthy control infants who had been born at the same hospital as the infant with intussusception. Information on vaccinations was verified by the provider. Results: Data were analyzed for 429 infants with intussusception and 1763 matched controls in a case-control analysis as well as for 432 infants with intussusception in a case-series analysis. Seventy-four of the 429 infants with intussusception (17.2 percent) and 226 of the 1763 controls (12.8 percent) had received RRV-TV (P=0.02). An increased risk of intussusception 3 to 14 days after the first dose of RRV-TV was found in the case-control analysis (adjusted odds ratio, 21.7; 95 percent confidence interval, 9.6 to 48.9). In the case-series analysis, the incidence-rate ratio was 29.4 (95 percent confidence interval, 16.1 to 53.6) for days 3 through 14 after a first dose. There was also an increase in the risk of intussusception after the second dose of the vaccine, but it was smaller than the increase in risk after the first dose. Assuming full implementation of a national program of vaccination with RRV-TV, we estimated that 1 case of intussusception attributable to the vaccine would occur for every 4670 to 9474 infants vaccinated. Conclusions: The strong association between vaccination with RRV-TV and intussusception among otherwise healthy infants supports the existence of a causal relation. Rotavirus vaccines with an improved safety profile are urgently needed. (N Engl J Med 2001;344:564-72.) Copyright (C) 2001 Massachusetts Medical Society.
引用
收藏
页码:564 / 572
页数:9
相关论文
共 34 条
[1]   Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein [J].
Ball, JM ;
Tian, P ;
Zeng, CQY ;
Morris, AP ;
Estes, MK .
SCIENCE, 1996, 272 (5258) :101-104
[2]   Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries [J].
Bresee, JS ;
Glass, RI ;
Ivanoff, B ;
Gentsch, JR .
VACCINE, 1999, 17 (18) :2207-2222
[3]  
Chen RT, 2000, B WORLD HEALTH ORGAN, V78, P186
[4]   Species specificity and interspecies relatedness of NSP4 genetic groups by comparative NSP4 sequence analyses of animal rotaviruses [J].
Ciarlet, M ;
Liprandi, F ;
Conner, ME ;
Estes, MK .
ARCHIVES OF VIROLOGY, 2000, 145 (02) :371-383
[5]   Public health considerations for the introduction of new rotavirus vaccines for infants: A case study of tetravalent rhesus rotavirus-based reassortant vaccine [J].
Clemens, J ;
Keckich, N ;
Naficy, A ;
Glass, R ;
Rao, M .
EPIDEMIOLOGIC REVIEWS, 1999, 21 (01) :24-42
[6]   COMPARISON OF THE ROTAVIRUS NONSTRUCTURAL PROTEIN NSP1 (NS53) FROM DIFFERENT SPECIES BY SEQUENCE-ANALYSIS AND NORTHERN BLOT HYBRIDIZATION [J].
DUNN, SJ ;
CROSS, TL ;
GREENBERG, HB .
VIROLOGY, 1994, 203 (01) :178-183
[7]  
Ein SH, 1997, PEDIATR SURG INT, V12, P374
[8]  
Farrington CP, 1996, AM J EPIDEMIOL, V143, P1165
[9]  
Farrington CP, 1998, AM J EPIDEMIOL, V147, P93
[10]  
FRIEDMAN MG, 1993, CLIN EXP IMMUNOL, V92, P194, DOI 10.1111/j.1365-2249.1993.tb03379.x